BLINATUMOMAB

Information current as at: 1 June 2026

PBAC meeting date: July 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Blincyto®
Form and strength:
  • Powder for I.V. infusion 38.5 micrograms
Submission sponsor:
AMGEN AUSTRALIA PTY LIMITED
Condition/indication:
(therapeutic use)
  • Acute lymphoblastic leukaemia (ALL) Precursor B-cell ALL (Pre-B-cell ALL)
Listing requested:
To request revision of the current combined blinatumomab/inotuzumab ozogamicin Risk Sharing Arrangement (RSA) for ALL and Pre-B-cell ALL.
Funding program:
PBS Section 100 (Efficient Funding of Chemotherapy)
Request authority level:
Authority Required
PBAC Submission type:
Change to existing listing (–)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
July 2026 PBAC meeting
Opportunity for consumer comment:
Open 25/03/2026 and close 20/05/2026 (see PBS Website)
3PBAC meeting:
Has not yet occurred
4PBAC outcome published:
Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
1215
Page last updated
31 May 2026
Return to the Medicine Status Listing
v.9.19